Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]
In development
Reference number: GID-TA10981
Expected publication date:
At the appraisal committee meeting in May 2025, the committee was not able to recommend teplizumab because more evidence is needed. The appraisal has had a short pause while NICE worked to identify how additional information can be obtained, and is now proceeding with a draft guidance consultation. A second committee discussion has been scheduled.